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Timotheos G. Kelpis, MD, Nikolaos E. Mezilis, MD, FESC, Vlasis N. Ninios, MD, MRCP, and
Antonis A. Pitsis, MD, FETCS, FESC, Thessaloniki, GreeceTranscatheter aortic valve implantation for treatment of
patients with severe symptomatic aortic stenosis and high
surgical risk has been well described. We report on the first
minimally invasive transapical aortic valve-in-a-valve
(VinV) implantation for severe aortic regurgitation in
a degenerated stentless bioprosthesis (Toronto stentless por-
cine valve [SPV]; St Jude Medical, Inc, St Paul, Minn) using
the Edwards SAPIEN transcatheter heart valve (THV)
(Edwards Lifesciences, Irvine, Calif).
Transcatheter aortic valve replacement constitutes a safe,
feasible, and effective technique in patients with severe
symptomatic aortic stenosis and high surgical risk for con-
ventional aortic valve replacement.1 Ever since its introduc-
tion by Cribier and colleagues,2 it has been used to treat
degenerative calcific stenosis of the native aortic valve in se-
lected patients.3 Transcatheter aortic valve deployment in
failed, surgically implanted, stented aortic bioprostheses
has been described with encouraging initial results.4,5 We re-
port on the first transapical transcatheter VinV procedure for
the treatment of severe aortic regurgitation in a degenerated
stentless bioprosthesis using the Edwards SAPIEN THV.
CLINICAL SUMMARY
An 80-year-old male patient presented with symptomatic
(New York Heart Association class IV) aortic stentless xe-
nograft regurgitation 9 years after aortic valve replacement
with a 25-mm Toronto SPV. Medical history was significant
for hypertension and chronic obstructive pulmonary disease.
Transesophageal echocardiography evaluation revealed
a bioprosthetic aortic valve with severe aortic valve regurgi-
tation (pressure half-time ¼ 197 ms) (Figure 1, A). There
was moderate mitral and tricuspid valve regurgitation with
systolic pulmonary artery pressure of 65 mm Hg and severe
left ventricular hypertrophy with preserved systolic function
(ejection fraction, 50%). Coronary angiography showed
a nonobstructive lesion in the proximal left anterior descend-
ing artery. Computed tomography angiographic assessment
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ascending aorta and proximal aortic arch.
Logistic European System for Cardiac Operative Risk
Evaluationpredicted risk for deathwas37.3%, and theSociety
of Thoracic Surgeons risk assessment was 27.5%. The patient
was then considered for transapical transcatheter aortic valve
implantation because of the increased perioperative risk, al-
though logistic European System for Cardiac Operative Risk
Evaluation may overestimate mortality in high-risk patients
undergoing isolated aortic valve replacement.
FIGURE 1. A, Preoperative transesophageal echocardiography: Mid-
esophageal long-axis view showing severe regurgitation of the aortic bio-
prosthesis. LA, Left atrium; LV, left ventricle; Ao, aorta. B, Postoperative
transesophageal echocardiography: Mid-esophageal long-axis view show-
ing normal function of the Edwards SAPIEN THV (Edwards Lifesciences,
Irvine, CA).rgery c October 2009
Brief Technique ReportsFIGURE 2. A, Valve positioning. B, Valve deployment. C, Final result.Valve size selection was done according to the routine
echocardiography findings: left ventricular outflow tract
measured at transthoracic echocardiogram long-axis mid-
esophageal view, in zoom mode, from the hinge points of
the noncoronary to the right coronary cusp. The annulus
diameter was 19 mm.
The operation was performed in a hybrid operating theater
under general anesthesia. After a left anterior mini-thora-
cotomy and pericardiotomy, 2 apical pursestring sutures
(pledgeted 0 Prolene; Ethicon Inc, Somerville, NJ) were
placed. After direct puncture of the apex of the heart,
a stiff-J guidewire (Amplatz super stiff, 180 cm; Boston Sci-
entific, Natick, Mass) was introduced through the aortic arch
down to the descending aorta. During rapid ventricular pac-
ing, at 200 beats/min, adequate dilatation of the degenerated
bioprosthesis was achieved with a 20-mm Ascendra aortic
balloon valvuloplasty catheter (Edwards Lifesciences).
After insertion of the 26F transapical delivery sheath, the
VinV implantation of a 23-mm Edwards SAPIEN THV
was performed on the beating heart. The valve was success-
fully deployed and firmly positioned without any migration
(Figure 2, A–C). No perivalvular or transvalvular leak
was noted, and good hemodynamic function was observedThe Journal of Thoracic and Ca(Figure 1, B). The patient had an uneventful hospital course
and was discharged on postoperative day 7.
At 3 months of follow-up, the patient remained free of
symptoms (New York Heart Association I). The echocardio-
gram showed no peri- or transvalvular leak and preserved
functionality of the left ventricle (left ventricular ejection
fraction, 60%) with trivial mitral regurgitation.
DISCUSSION
Percutaneous heart valve implantation (Cribier Edwards;
Edwards Lifesciences) in the aortic position was performed
by Cribier and colleagues in 2002.2 The first percutaneous
heart valve (CoreValve; CoreValve Inc, Paris, France) pro-
cedure for the treatment of a severely insufficient surgically
implanted stented bioprosthesis (Mitroflow; Sorin Group,
Vancouver, British Columbia, Canada) in the aortic posi-
tion was reported by Wenaweser and colleagues4 in 2007.
Subsequently in 2008, Walther and colleagues5 reported
the transapical VinV implantation of an Edwards Sapien
THV inside a stented Edwards Perimount conventional xe-
nograft.
We report, to the best of our knowledge, on the first suc-
cessful transapical transcatheter VinV procedure to treatrdiovascular Surgery c Volume 138, Number 4 1019
Brief Technique Reportssevere regurgitation of an aortic stentless bioprosthesis
(Toronto SPV) using the Edwards SAPIEN THV.
CONCLUSIONS
There is a current worldwide trend toward preferential
use of biological rather than mechanical aortic prostheses
in younger age groups. The expanding applicability of
minimally invasive techniques may augment this trend,
further lowering the recommended age for tissue aortic
valve recipients. The stentless valve design may prove ad-
vantageous in case of subsequent VinV therapy. If this
proves to be true, it could lead to an increased use of stent-
less valves. The role of the transcatheter VinV procedure
as an alternative to conventional redo aortic valve replace-
ment needs to be determined. Clearly, this technique and
platform will play a role in the future, with the parameters‘‘Valve-in-valve’’ implantation in a p
bioprosthesis and severe intraprosthe
David Attias, MD, Dominique Himbert, MD, Ulrik Hvass
An 80-year-old man was admitted to our department for
dyspnea (New York Heart Association class III) and angina
pectoris. His medical history included an aortic valve re-
placement (AVR) for aortic stenosis with a size 25 stentless
bioprosthesis associated with a coronary bypass (left internal
thoracic artery to the left anterior descending coronary artery
and saphenous vein to the right coronary artery) in 1999 and
a myocardial infarction in 2004. In 2008, infective endocar-
ditis owing to Streptococcus gallolyticus was adequately
treated by intravenous amoxicillin over 6 weeks, as well as
gentamicin for 15 days, and currently was complicated by
severe intraprosthetic aortic regurgitation (AR).
On admission, 1 month after complete healing of the en-
docarditis, blood pressure was 142/43 mm Hg, and clinical
signs of severe AR and congestive heart failure were present.
Transthoracic and transesophageal echocardiography (TEE)
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showed severe intraprosthetic AR owing to perforation and
prolapse of the posterior cusp (Figure 1, A), left ventricular
dilatation, and preserved left ventricular ejection fraction.
Neither vegetations, abscesses, nor paraprosthetic leaks
were noted. There were no biological signs of ongoing infec-
tion and all blood cultures were negative.
A coronary angiogram showed occlusion of the three
native vessels and a patent left internal thoracic graft, but
occlusion of the saphenous vein–right coronary bypass.
Finally, preoperative computed tomography discovered
a limited pulmonary cancer, indicating surgical lobectomy.
The mortality risk was 26% as predicted by the Euro-
SCORE and 18% according to The Society of Thoracic Sur-
geons Predicted Risk of Mortality. After multidisciplinary
evaluation, transcatheter aortic valve implantation (TAVI)
was considered on a compassionate basis to permit thoracic
surgery. After informed consent, a 29-mm CoreValve Re-
valving System (Medtronic, Inc, Minneapolis, Minn) was
implanted into the stentless bioprosthesis via percutaneous
femoral access using a 10F Prostar XL device (Abbott
Vascular, Inc, Abbott Park, Ill) as the pre-closing device.
The procedure was performed in the catheterization labora-
tory, under general anesthesia, with fluoroscopic and TEE
guidance. Technical aspects of CoreValve Revalving
System implantation have previously been detailed.1
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